Epcoritamab (Gen3013; Duobody-Cd3xcd20) To Induce Complete Response In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-Nhl): Complete Dose Escalation Data And Efficacy Results From A Phase I/Ii Trial.

Martin Hutchings,Pieternella Lugtenburg,Rogier Mous,Michael Roost Clausen,Martine Chamuleau,Kim Linton,Simon Rule,Juanita Suzanne Lopez,Roberto S Oliveri,Dena DeMarco,Brian Elliott,Peter Johnson

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 21|浏览4

暂无评分

摘要

8009Background: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results for the treatment of pts with R/R B-NHL. Epcoritamab is a novel subcutaneously administered bsAb with a fa...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要